From the molecular changes occurring in taste perception to its application in young patients with complex metabolic needs, and finally to its effectiveness across psychiatric populations, these investigations illuminate both the mechanisms and clinical utility of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing obesity and its complications
At the end of the trial, mean weight loss of 4.4% is reported in the combination group, compared to 1.6% for placebo
Regulatory Status Disclosure: The FDA declared the semaglutide drug shortage resolved in February 2025 and the tirzepatide drug shortage resolved in October 2024
Impaired autophagy in the follicle can decrease oocyte quality, contributing to infertility in women (Li et al., 2019)
Cross-trial inference can motivate a hypothesis
The North American GLP-1 agonists market is expected to register the highest market share in revenue in the near future